MARLBOROUGH, Mass., April 06, 2023 (GLOBE NEWSWIRE) — Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the first quarter of 2023 after the market close on Monday, May 8th, 2023. Company management will host a conference call to discuss financial results at 5:00 p.m. ET.
Investors interested in listening to the conference call are required to register online. It is recommended to register at least a day in advance. A live and archived webcast of the event will be available on the “Investors” section of the Akoya website at https://investors.akoyabio.com/.
About Akoya Biosciences
As The Spatial Biology Company®, Akoya Biosciences’ mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. Akoya offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research via its key platforms: PhenoCycler™, PhenoImager™ Fusion and PhenoImager HT. To learn more about Akoya, visit www.akoyabio.com.
Investor Contact:
Priyam Shah
Sr. Director, Investor Relations
Akoya Biosciences, Inc.
investors@akoyabio.com
Media Contact:
Christine Quern
(617) 650-8497
media@akoyabio.com
VALENCIA, Calif.--(BUSINESS WIRE)--SetPoint Medical, a commercial-stage medical technology company dedicated to improving care for people…
NEW YORK--(BUSINESS WIRE)--SK Capital Partners, LP (“SK Capital”), a New York-based private investment firm focused…
Atlanta, Georgia--(Newsfile Corp. - December 15, 2025) - Apyron, Inc. is a medical technology company…
EXXUA is now available through Aytu RxConnect® pharmacies to ensure optimal access and availabilityEXXUA has…
SBS-IF is the second orphan disease target indication for Jaguar's intestinal failure program, which includes…
mNEXSPIKE is Moderna's third product to receive a positive CHMP opinion alongside Spikevax (COVID-19 Vaccine,…